Results 241 to 250 of about 346,103 (330)

Evolving Recommendations for Patient Populations Among Oncology Medicines: A Quantitative and Qualitative Analysis

Clinical Pharmacology &Therapeutics, EarlyView.
After a medicine has been tested in pivotal trials, regulators, health technology assessment (HTA) organizations, and professional societies make decisions about the patients best served by the medicine. This study assesses how the patient populations for oncology medicines (2010–2023) are defined (1) at trial, (2) regulatory submission, (3) upon ...
Milou A. Hogervorst, Rick A. Vreman, Theresa A. Oduol, Aukje K. Mantel‐Teeuwisse, Wim G. Goettsch, Aaron S. Kesselheim   +5 more
wiley   +1 more source

Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia. [PDF]

Eur J Med Res
Shu W, Yang Q, He D, Li Y, Le J, Cai Q, Dai H, Luo L, Chen B, Gong Y, Jin D.   +10 more
europepmc   +1 more source

Comprehensive DSRCT multi‐omics analyses unveil CACNA2D2 as a diagnostic hallmark and super‐enhancer‐driven EWSR1::WT1 signature gene

Cancer Communications, EarlyView.
Florian Henning Geyer, Alina Ritter, Seneca Kinn‐Gurzo, Tobias Faehling, Jing Li, Armin Jarosch, Carine Ngo, Endrit Vinca, Karim Aljakouch, Azhar Orynbek, Shunya Ohmura, Thomas Kirchner, Roland Imle, Laura Romero‐Pérez, Juan Díaz‐Martín, Stefanie Bertram, Enrique de Álava, Clémence Henon, Sophie Postel‐Vilnay, Ana Banito, Martin Sill, Yvonne Versleijen‐Jonkers, Benjamin Friedrich Berthold Mayer, Martin Ebinger, Monika Sparber‐Sauer, Sabine Stegmaier, Daniel Baumhoer, Wolfgang Hartmann, Jeroen Krijgsveld, David Horst, Olivier Delattre, Patrick Joseph Grohar, Thomas Georg Phillip Grünewald, Florencia Cidre‐Aranaz   +33 more
wiley   +1 more source

Differentiating reactive and neoplastic gamma‐delta (γδ) T‐cell expansions in the peripheral blood and bone marrow

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract The clinical and immunophenotypic attributes of reactive γδ T‐cell expansions are less well characterized than their malignant counterparts, which can pose diagnostic challenges. This study aims to investigate the characteristics and long‐term clinical outcomes of reactive γδ T‐cell expansions.
Hamza Tariq, Zubair Ilyas, Lucy Fu, Yijie Liu, Qing Ching Chen, Kristy Wolniak, Yi‐Hua Chen   +6 more
wiley   +1 more source

Diagnostic approach to leukemia cutis : A differential diagnostic step-by-step algorithm. [PDF]

Am J Clin Pathol
Jenei A, Tzankov A.
europepmc   +1 more source

Chronic myeloid leukemia

HemaSphere, 2018
openaire   +2 more sources

TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes [PDF]

, 2016
et al,, Fronick, C. C., Fulton, R. S., Ley, T. J., Miller, C. A., O\u27Laughlin, M., Petti, A. A., Wartman, L. D., Wilson, R. K.   +8 more
core   +2 more sources

Longitudinal monitoring of class‐switched memory‐B cell proportions identifies plausible germinal center failure in patients with suspected immune disorders

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract A reduced proportion of peripheral class‐switched memory B cells (CSM‐B cells) is presumed to indicate ineffective germinal activity. The extent that this finding corresponds to a plausible germinal center failure pathophysiology in patients not diagnosed with CVID or hyper IgM syndrome is not known.
Vijaya Knight, Olivia Starich, Cullen M. Dutmer, Jordan K. Abbott   +3 more
wiley   +1 more source

Association Between B-Cell Marker Expression and <i>RUNX1</i> Lesions in Acute Myeloid Leukemia, Beyond <i>RUNX1</i>::<i>RUNX1T1</i> Fusion: Diagnostic Pitfalls with Mixed-Phenotype Acute Leukemia-B/Myeloid. [PDF]

Cancers (Basel)
George GV, Kajstura M, Jajosky AN, Fang H, Jelloul FZ, Evans AG, Burack WR, Bennett JM, Medeiros LJ, Wang W, El Hussein S.   +10 more
europepmc   +1 more source

Chronic Myeloid Leukemia

, 2020
openaire   +3 more sources